Drug that delays onset of type 1 diabetes gets approval in US
New ScientistNov 29, 2022
The Facts
Researchers in the US, Australia, and China have developed smart insulins that mimic and respond to the body's natural response to changing blood sugar levels.
The novel insulin, which can be activated only when needed, could reduce the frequency of Type 1 diabetes treatments to just once a week rather than up to 10 times a day.
The Spin
Narrative A
This development not only promises to reduce the frequency of treatments, but also to significantly reduce the risk of long-term health complications. Additionally, it could free millions of Type 1 diabetes patients from the constant need for glucose monitoring, thereby easing both physical and mental burdens of the condition.
Narrative B
While this treatment could be promising, accessibility and affordability remain critical issues. Only when older, cheaper versions of the drug are discontinued and unhealthy competition is checked can these game-changing insulins replace existing treatments and improve diabetics' lives.
